Survodutide Once Weekly for the Treatment of Adults with Obesity
Authors' conclusion
Survodutide led to significantly greater reductions in body weight than placebo in adults with obesity without diabetes.
Study context
- Population
- Adults with body-mass index (BMI) ≥30, or ≥27 with ≥1 obesity-related complication (excluding diabetes); mean age 47.1 years, 40.6% men, mean BMI 37.9, mean body weight 108.8 kgrandomized 1:1:1
- Participants
- 725 adults
- Comparison
- Once-weekly SC survodutide 3.6 mg or 6.0 mg vs placebo, plus lifestyle counseling
- Survodutide 3.6 mgn = 241
- Survodutide 6.0 mgn = 242
- Placebon = 242reference
- Primary endpoint
- Two primary end points: percent change in body weight and body-weight reduction ≥5% from baseline
- Follow-up
- Week 76
Methodological detailsphase 3, double-blind, placebo-controlled
- Phase 3
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Mean % change in body weight from baseline
Mean % change in body weight from baseline · week 76 Survodutide 3.6 mg mean −12.2 (CI −13.6–-10.8) % · Survodutide 6.0 mg mean −13.0 (CI −14.4–-11.6) % · Placebo mean −5.4 (CI −6.9–-4.0) %
Weight reduction ≥5%
- Survodutide 3.6 mg vs Placebo: P < 0.001 for all comparisons with placebo
- Survodutide 6.0 mg vs Placebo: P < 0.001 for all comparisons with placebo
Further findings
- No deaths were reported
Safety
Gastrointestinal adverse events (most common; typically mild to moderate)
Original publication
Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. Published 7 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →